Prediabetes linked to excess glucagon in transgenic mice with pancreatic active AKT1

Toya M Albury-Warren1, Veethika Pandey1, Lina P Spinel1, Michal M Masternak1,2 and Deborah A Altomare1

1Burnett School of Biomedical Sciences, College of Medicine, University of Central Florida, 6900 Lake Nona Boulevard, Orlando, Florida 32827, USA
2Department of Head and Neck Surgery, The Greater Poland Cancer Centre, 61-866 Poznan, Poland

Abstract

Protein kinase B/AKT has three isoforms (AKT1–3) and is renowned for its central role in the regulation of cell growth and proliferation, due to its constitutive activation in various cancers. AKT2, which is highly expressed in insulin-responsive tissues, has been identified as a primary regulator of glucose metabolism as Akt2 knockout mice (Akt2−/−) are glucose-intolerant and insulin-resistant. However, the role of AKT1 in glucose metabolism is not as clearly defined. We previously showed that mice with myristoylated Akt1 (AKT1Myr) expressed through a bicistronic Pdx1-TetA and TetO-MyrAkt1 system were susceptible to islet cell carcinomas, and in this study we characterized an early onset, prediabetic phenotype. Beginning at weaning (3 weeks of age), the glucose-intolerant AKT1 Myr mice exhibited non-fasted hyperglycemia, which progressed to fasted hyperglycemia by 5 months of age. The glucose intolerance was attributed to a fasted hyperglucagonemia, and hepatic insulin resistance detectable by reduced phosphorylation of the insulin receptor following insulin injection into the inferior vena cava. In contrast, treatment with doxycycline diet to turn off the transgene caused attenuation of the non-fasted and fasted hyperglycemia, thus affirming AKT1 hyperactivation as the trigger. Collectively, this model highlights a novel glucagon-mediated mechanism by which AKT1 hyperactivation affects glucose homeostasis and provides an avenue to better delineate the molecular mechanisms responsible for diabetes mellitus and the potential association with pancreatic cancer.

Key Words

- insulin signaling
- glucagon
- glucose metabolism
- pancreas
- oncogenes

Introduction

AKT, a serine/threonine kinase, is downstream of phosphatidylinositol-3-kinase (PI3K) and growth factor receptors (e.g. epidermal growth factor receptor), and is a hallmark signaling protein predominantly recognized for regulation of cell survival, growth, and proliferation. AKT signals through the phosphorylation and subsequent activation or inhibition of downstream substrates, such as mammalian target of rapamycin complex 1 (mTORC1) or glycogen synthase kinase 3 beta (GSK-3beta), respectively (Hemmings & Restuccia 2012). AKT hyperactivation in various cancers has been studied (Altomare & Testa 2005, Cheung & Testa 2013), while its role in glucose metabolism has been noted but comparatively overlooked until analysis of AKT isoform knockout mice.
Although analogous in structure, AKT isoforms (AKT1, AKT2, and AKT3) are encoded by three different genes, which are differentially expressed in tissues and have varying functions (Hay 2011). While Akt1 is ubiquitously expressed in mammalian tissues, it was initially deemed unnecessary for glucose homeostasis as Akt1 knockout mice (Akt1<sup>−/−</sup>) have impaired fetal and adulthood growth, but normal glucose tolerance and insulin signaling (Chen et al. 2001b). Akt3 is primarily expressed in the brain and was also reported unnecessary for glucose homeostasis with Akt3<sup>−/−</sup> mice exhibiting reduced brain size and weight, but normal glucose regulation (Tschopp et al. 2005). In contrast, Akt2 is highly expressed in insulin responsive tissues and has been identified as a primary regulator of glucose metabolism, as Akt2 knockout mice (Akt2<sup>−/−</sup>) are prediabetic with insulin resistance, hyperinsulinemia and glucose intolerance (Cho et al. 2001a, Garofalo et al. 2003).

A role for AKT1 in glucose homeostasis became evident with the metabolic analysis of compound isoform knockout mice (Chen et al. 2009). Similar to Akt2<sup>−/−</sup> mice, Akt1<sup>+/+</sup>/Akt2<sup>−/−</sup>/Akt3<sup>−/−</sup> mice were mildly diabetic, suggesting that the loss of Akt3 was inconsequential. Conversely, haploinsufficiency of Akt1 in Akt2<sup>−/−</sup> mice resulted in a more severe diabetic phenotype, characterized by fed and fasted hyperglycemia, glucose intolerance, insulin resistance, and hyperinsulinemia. Additional crosses of Akt1<sup>+/−</sup>/Akt2<sup>−/−</sup> mice with mice haploinsufficient for tumor suppressor phosphatase and tensin homolog (PTEN<sup>+/−</sup>), an upstream regulator of AKT activation, significantly improved glucose homeostasis and demonstrated the compensatory nature and importance of Akt1, contrary to previous reports (Cho et al. 2001b). Although AKT1 hyperactivation has been frequently observed in pancreatic cancers (Schlieman et al. 2003, Missiaglia et al. 2010), there are limited studies regarding AKT1 hyperactivation and glucose homeostasis, except for attempts to improve the success rates of human islet transplantation therapy for diabetic patients (Bernal-Mizrachi et al. 2001, Tuttle et al. 2001, Kushner et al. 2005, Stiles et al. 2006). Hyperactivation of AKT1 in pancreatic β-cells, via PTEN deletion (Kushner et al. 2005, Stiles et al. 2006) or in mice with a myristoylated Akt1 (Bernal-Mizrachi et al. 2001, Tuttle et al. 2001) under expression of a rat insulin promoter (RIP), led to hypoglycemia, hyperinsulinemia and improved glucose tolerance, due to increased β-cell mass, size, and proliferation.

We recently characterized aged mice with myristoylated, membrane-bound Akt1 (AKT1<sup>Myr</sup>) expressed using the Pdx promoter (Albury et al. 2015) and found that ~25% of mice developed islet cell carcinomas after 1 year of age. Here we report that this strain of mice exhibit non-fasted hyperglycemia as early as weaning and fasted hyperglycemia by 20 weeks of age, thus presenting a potentially unique opportunity to study the mechanistic cross-talk between diabetes and cancer. We show that the pre-diabetic phenotype can be attributed to the AKT1<sup>Myr</sup> transgene, as it is tetracycline-regulatable, and down-regulation of the AKT1<sup>Myr</sup> transgene reduced the non-fasted and fasted hyperglycemia to WT levels. Collectively, metabolic characterization of the AKT1<sup>Myr</sup> mice revealed a novel glucagon-mediated mechanism by which AKT1 hyperactivation affects glucose homeostasis.

**Materials and methods**

**Animals**

All mice were housed and handled according to protocols approved by the University of Central Florida (UCF) Institutional Animal Care and Use Committee at the AAALAC accredited UCF Lake Nona Animal Facility. Transgenic mice with activation of AKT1 (Pdx-tTA;TetO-MyrAkt1) were mated as previously described (Albury et al. 2015). At 3 weeks, the pups were weaned and tail-snipped for DNA extraction and genotyping, as previously described (Albury et al. 2015). Mice with TetO-MyrAkt1, but lacking the knock-in Pdx-tTA, were classified as normal or WT littermates. Mice with Pdx-tTA and TetO-MyrAkt1 were classified as AKT1<sup>Myr</sup> mice having constitutively active AKT1 in the pancreas. Litters were placed on a standard control diet or a doxycycline diet (BioServ, Frenchtown, NJ, USA), which shuts off AKT1<sup>Myr</sup> transgene expression. All mice were euthanized according to American Veterinary Medical Association guidelines.

**Genotyping analysis**

Primers for PCRs for AKT1<sup>Myr</sup> mice were previously described (Albury et al. 2015). Akt2<sup>KO</sup> mice were obtained from J R Testa (Fox Chase Cancer Center, Philadelphia, PA, USA), and PCR primers detected the presence of WT or knockout Akt2 (5′-GATGAACTTCCAGGTCAGCT-3′; 5′-AGAGCTTCACTGGATAAGCT-3′; and 5′-TCTCTGTCACCTCCCATGAG-3′).

**Histological analysis**

Pancreatic tissue was fixed in 10% neutral buffered formalin (Surgipath Leica, Buffalo Grove, IL, USA) and embedded in paraffin for sectioning and processing as
previously described (Albury et al. 2015). Slides were stained for hematoxylin and eosin (Surgipath) or immunohistochemistry using the Polymer Refine Detection reagents (Leica) on the Bond-Max immunostainer (Leica). Antigen retrieval was optimized using sodium citrate (pH 6) or EDTA (pH 9) buffers (Leica). The following antibodies were used: phospho-Akt Ser473 (GeneTex, Irvine, CA, USA), also phospho-mTor Ser2448, phospho-S6 Ser235/236, glucagon, and insulin (all from Cell Signaling Technology, Danvers, MA, USA). All slides processed on the immunostainer were run with a negative control, which was treated with antibody diluent instead of the primary antibody, to ensure antibody specificity. Images were taken using a Leica DM 2000 microscope with 5×, 10×, or 40× objectives. Islet size was measured in the whole pancreas of three mice per genotype. The mice selected had no significant lesions at the time of necropsy, as described by a pathologist. The pancreas was sectioned into 5 μm sections and every 25th section was H&E stained. A total of 50 islets from three sections were analyzed per mouse. Islet diameter was determined using measuring tools available on an Axio Imaging System (Zeiss, Oberkochen, Germany).

Blood glucose measurement

Blood glucose levels were measured using a Contour Glucometer (Bayer) at weaning, 5, 7, 9, and 12 weeks. Weaning was at 3 weeks of age. Blood glucose levels were measured randomly, between 0900 and 1000 h, or after an overnight fast.

Glucose tolerance test

Mice were fasted overnight, weighed (g), i.p. injected with 2 IU/kg porcine insulin (Sigma) and blood glucose tested with a glucometer before injection, 15, 30, 45, and 60 min after injection. Blood glucose (mg/dl) vs time (min) was plotted and the area under the curve was calculated (GraphPad Prism 5).

Insulin tolerance testing

Mice were fasted for 2 h, weighed (g), i.p. injected with 2 IU/kg porcine insulin (Sigma) and blood glucose tested with a glucometer before injection, 15, 30, 45, and 60 min after injection. Blood glucose (mg/dl) vs time (min) was plotted and the area under the curve was calculated (GraphPad Prism 5).

Insulin stimulation

Mice were fasted overnight, weighed (g), anesthetized using isoflurane and injected with porcine insulin (10 IU/kg; Sigma) or saline via the inferior vena cava. After 2 min, mice were euthanized and the following tissues were snap-frozen in liquid nitrogen: pancreas, liver, perigonadal adipose tissue, and skeletal muscle. Tissues were homogenized using 15 mg zirconium oxide beads (1.0 mm for skeletal muscle and 0.5 mm for adipose, liver, and pancreas) with the Bullet Blender Homogenizer BBX24 (Next Advance, Averill Park, NY, USA). Proteins were extracted for ELISA analysis for AKT, AKT (pS473), insulin receptor (IR), and IR (pY1158) (all from Invitrogen). Data was analyzed using a four-parameter algorithm to construct the best fitting curve.

Statistical analysis

Results are reported as mean ± S.E.M. Comparisons were made between two and more than two groups using unpaired or paired Student’s t-tests and two-way ANOVA followed by Student’s t-tests within groups, respectively. All analysis used GraphPad Prism 5 with significance accepted at a P value of <0.05. Letters were used to illustrate significance, as multiple groups are being compared. Groups that do not share the same letter display a statistical significance of P<0.05.

Results

**AKT1<sup>M</sup> transgenic mice have tetracycline-regulatable AKT/mTOR pathway activation in the pancreas**

The AKT1<sup>M</sup> construct uses the Pdx1 promoter, which is important for pancreas development in utero and postnatal β-cell maintenance (Holland et al. 2002), to drive the expression of myristoylated and therefore active Akt1 within different pancreatic cell lineages. Expression of the Akt1<sup>M</sup> transgene is inhibited in the presence of the tetracycline analogue doxycycline. Immunohistochemistry (Fig. 1A), using phosho-specific antibodies, validated increased phosphorylated or active
AKT1, along with its downstream substrates mTORC1 and S6, in the islets of AKT1\textsuperscript{M}r mice given standard feed, as compared to WT mice on standard feed and doxycycline fed AKT1\textsuperscript{M}r mice. To quantify this result, protein was extracted from insulin-stimulated pancreatic tissue and measured via ELISA (Fig. 1B), confirming significantly elevated ($P<0.001$) AKT1 phosphorylation (Ser473) and thus activation in AKT1\textsuperscript{M}r mice vs WT mice. Pancreatic levels of phosphorylated AKT1 (Ser473) were eight times greater in AKT1\textsuperscript{M}r mice than WT mice, while phosphorylated AKT1 levels in doxycycline fed AKT1\textsuperscript{M}r mice were equal to those of WT mice, confirming the ability of doxycycline to turn off the transgene. Doxycycline treatment began at weaning and continued for 2 weeks, which was sufficient to decrease the activation of the AKT/mTOR pathway to WT levels. There was no significant difference in total AKT between groups.

**Reversible, non-fasted and fasted hyperglycemia in AKT1\textsuperscript{M}r transgenic mice**

At weaning, mice were tail snipped for genotyping and blood glucose tested. AKT1\textsuperscript{M}r mice ($n=10$), regardless of sex (Fig. 2G), had significantly higher ($P<0.0001$) non-fasted blood glucose levels at weaning than WT littermates (Fig. 2A). Non-fasted blood glucose levels were monitored biweekly for 9 weeks following weaning, and similarly, AKT1\textsuperscript{M}r mice had significantly higher ($P=0.0031$) non-fasted blood glucose levels at 12 weeks of age compared to WT mice (Fig. 2A).

To confirm that the non-fasted hyperglycemia was due to the Akt\textsuperscript{M}r transgene expression, doxycycline was administered to mice in order to turn off the transgene. Mating cages were arranged with half receiving standard feed and half receiving doxycycline feed for in utero exposure. Feeding regimens were continued at weaning and non-fasted blood glucose levels were monitored biweekly for 9 weeks. At weaning, the non-fasted blood glucose levels for AKT1\textsuperscript{M}r mice on a standard diet were significantly higher ($P<0.02$) than all other treatment groups. There was no significant difference between the AKT1\textsuperscript{M}r mice on doxycycline and the WT mice on either diet, and the same pattern was observed at 12 weeks (Fig. 2B). With regard to overnight fasting, 12-week AKT1\textsuperscript{M}r mice exhibited no significant difference in fasted glucose levels (Fig. 2C). However, aged AKT1\textsuperscript{M}r exhibited fasted hyperglycemia, a more severe diabetic phenotype, by 5 months of age (Fig. 2D), which was also attenuated by doxycycline treatment. Weight (Fig. 2E) and food intake (Fig. 2F) did not differ among genotypes.

**Figure 1**

AKT1\textsuperscript{M}r mice have doxycycline-regulatable AKT/mTOR pathway activation in the pancreas. Hyperactivation and decreased activation of the AKT/mTOR pathway in AKT1\textsuperscript{M}r mice on regular chow diet and AKT1\textsuperscript{M}r mice on doxycycline diet respectively, confirmed with: (A) immunostaining of representative pancreatic tissue using phospho-AKT (Ser473), phospho-mTOR (Ser2448), and phospho-S6 (Ser235/236) antibodies (40× objective; scale bar 50 μm) and (B) analysis of protein from pancreatic tissue using a phospho-AKT1 (Ser473) ELISA. Two-way ANOVA followed by Student’s t-tests within groups were used to analyze the data. Data represented as mean ± S.E.M. ($n=5$). All phospho-AKT1 measurements were normalized to their total AKT measurements. Reg, regular chow diet; Dox, doxycycline diet. Letters were used to illustrate significance as multiple groups are being compared (see the ‘Materials and methods’ section for explanation). A full colour version of this figure is available at http://dx.doi.org/10.1530/JOE-15-0288.
Glucose intolerance in AKT1Myr transgenic mice due to insulin–glucagon imbalance

GTT was performed at 12 weeks (n = 5 males) to analyze the ability of AKT1Myr mice to clear glucose from the blood. AKT1Myr mice had a significantly higher (P = 0.0049) area under the curve (Fig. 3B) compared to WT mice. The significantly elevated blood glucose levels began at 30-min post injection and continued for the duration of the test, signifying glucose intolerance (Fig. 3A).

Glucose intolerance in AKT1Myr transgenic mice due to insulin–glucagon imbalance

GTT was performed at 12 weeks (n = 5 males) to analyze the ability of AKT1Myr mice to clear glucose from the blood. AKT1Myr mice had a significantly higher (P = 0.0049) area under the curve (Fig. 3B) compared to WT mice. The significantly elevated blood glucose levels began at 30-min post injection and continued for the duration of the test, signifying glucose intolerance (Fig. 3A).

Glucose intolerance in AKT1Myr transgenic mice was compared and found to be similar to the well-established, prediabetic Akt2-null mouse model (AKT2KO; Fig. 3C). However,
serum insulin and glucagon levels, collected via cheek bleeding, revealed significant differences between AKT1Myr and AKT2KO mice. AKT2KO mice had significantly (P < 0.02) elevated insulin levels, which were evident before the glucose injection (0 min) and 45 min after the injection (Fig. 3D and Table 1). When compared to WT mice, AKT1Myr mice did not initially (0 min) have elevated insulin levels. However, insulin levels were significantly (P < 0.009) higher 45 min after the injection.

Serum glucagon levels in AKT2KO mice were similar to WT mice (Fig. 3E and Table 1). However, AKT1Myr mice had significantly (P < 0.05) elevated fasting glucagon levels (0 min), which returned to WT levels by the 45-min time point. In addition to functional differences in pancreatic α-cells, AKT1Myr mice had an altered distribution of α-cells throughout the pancreatic islets (Fig. 3F), typical of several diabetic murine models (Bates et al. 2008, Cummings et al. 2008).

Figure 3
Glucose intolerance in AKT1Myr mice due to insulin–glucagon imbalance. Glucose tolerance testing (GTT; n = 5) was performed at 12 weeks comparing (A) WT and AKT1Myr (MYR AKT1) mice and (C) WT, MYR AKT1, and Akt2−/− (AKT2 KO) mice (P < 0.05). (B) Area under the curve. Data represented as mean ± S.E.M. (P = 0.0049). Blood was collected, via cheek bleeds, at the 0- and 45-min time points to analyze serum (D) insulin and (E) glucagon levels using ELISAs. Insulin and glucagon values are also provided in Table 1. (F) Immunostaining of pancreatic tissue using insulin and glucagon antibodies (objective 40×; scale bar 50 μm). Unpaired Student’s t-tests were used to analyze differences in area under the curve and the GTT time points. Two-way ANOVA followed by Student’s t-tests within groups were used to analyze the data for D and E. Letters were used to illustrate significance as multiple groups are being compared (see the ‘Materials and methods’ section for explanation). A full colour version of this figure is available at http://dx.doi.org/10.1530/JOE-15-0288.
Insulin resistance in the liver of AKT1Myr transgenic mice

One week following the GTT, an insulin tolerance test (n = 5 males) was performed to analyze the sensitivity of insulin-responsive tissues in AKT1Myr mice. Area under the curve was calculated (Fig. 4A), in regard to blood glucose vs time, and was not significantly different when comparing AKT1Myr mice and WT mice. However, at the 15-min time point the AKT1Myr mice had significantly higher (P = 0.035) blood glucose levels than the WT mice (Fig. 4B).

To further analyze insulin signaling, mice were injected with 10 IU/kg porcine insulin (n = 5 males) or saline (n = 5 males) via the inferior vena cava. Analysis of liver tissue revealed significantly decreased IR phosphorylation (Fig. 4C) in AKT1Myr mice, compared to WT mice, despite no significant difference in IR levels. There were no differences in IR phosphorylation in adipose or muscle tissue (Fig. 4D and E). Calculation of the HOMA-IR confirmed insulin resistance in AKT1Myr mice, as compared to WT mice (Fig. 4F).

Decreased pancreas and islet size, with aging, in AKT1Myr mice

Pancreas size was measured upon euthanization and dissection using a digital scale (n = 5) in 12-week- (Fig. 5A) and 16-month- (Fig. 5B) old mice. The pancreas size in the young AKT1Myr mice was not significantly different. However, the pancreas size in the aged 16-month-old AKT1Myr mice was significantly smaller (P = 0.0049) than WT mice. Islet size (n = 50 islets) was also measured at 12 weeks (Fig. 5C) and 16 months (Fig. 5D). Islet diameter was not significantly different in 12-week-old mice, but significantly decreased (P = 0.008) in 16-month-old mice.

Discussion

In this study we characterized the early onset, prediabetic phenotype observed in AKT1Myr mice and highlighted a novel mechanism by which AKT1 hyperactivation affects glucose homeostasis. AKT1Myr mice, previously described for their aged onset islet cell carcinomas (Albury et al. 2015), have bicistronic regulation of myristoylated Akt1 through a Pdx1-TetA and TetO-MyrAkt1 system. This allows the expression of myristoylated, membrane-bound and thus activated AKT1 in the pancreas except in the presence of doxycycline, a tetracycline analogue. The Pdx1 promoter, which is important for pancreas development in utero and postnatal β-cell maintenance (Holland et al. 2002), drives expression within the pancreatic progenitor cells, which eventually give rise to the endocrine cells (islets of Langerhans), exocrine cells (acini cells) and ductal cells of the pancreas (Hale et al. 2005). The hyperactivation of AKT1 throughout all cell types of the pancreas distinguishes this model from other constitutively active AKT1 mouse models, which use a RIP to drive expression in the β-cells (Bernal-Mizrachi et al. 2001, Tuttle et al. 2001). Additionally, the use of different tissue-specific promoters highlights the important role of expression patterns and cellular localization for AKT function.

The novelty of the glucose deregulation in AKT1Myr mice is further elucidated when compared to the known, prediabetic Akt2-null mouse model (AKT2KO). As previously reported, AKT2KO mice have fasted and fed hyperglycemia beginning at 5 and 10 weeks in males and females, respectively (Garofalo et al. 2003). Male mice progress to a severe form of diabetes by 5 months of age and females remain prediabetic until 12 months of age (Cho et al. 2001a). Conversely, AKT1Myr mice, regardless of sex, exhibited non-fasted hyperglycemia at weaning. There was an increase in severity with time as fasted hyperglycemia was not detectable until 5 months of age. To confirm that the hyperglycemia was due to the Akt1Myr transgene expression, doxycycline was administered to the mice to turn off the transgene. Doxycycline treatment reduced AKT1Myr blood glucose to WT levels, confirming that the fasted and non-fasted hyperglycemia in AKT1Myr mice was due to AKT1 hyperactivation. Other possible contributing factors, such as weight and food intake, were ruled out, further distinguishing the AKT1Myr mice from the lighter AKT2KO mice (Garofalo et al. 2003) and heavier obese diabetic mouse models (i.e. db/db, NZO, and TALLYHO mice) (Herberg et al. 1970, Coleman 1982, Kim et al. 2006).

Table 1 The average insulin and glucagon serum levels in WT, MYR AKT1, and AKT2 KO mice during the glucose tolerance test

<table>
<thead>
<tr>
<th>Time post glucose injection</th>
<th>WT</th>
<th>MYR AKT1</th>
<th>AKT2 KO</th>
</tr>
</thead>
<tbody>
<tr>
<td>Average insulin levels (μg/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 min</td>
<td>0.50</td>
<td>0.68</td>
<td>3.0a (P &lt; 0.02)</td>
</tr>
<tr>
<td>45 min</td>
<td>0.54</td>
<td>1.14 (P = 0.009)</td>
<td>3.5a (P &lt; 0.02)</td>
</tr>
<tr>
<td>Average glucagon levels (pmol/l)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>0 min</td>
<td>1.38</td>
<td>2.18a (P &lt; 0.05)</td>
<td>0.84</td>
</tr>
<tr>
<td>45 min</td>
<td>1.42</td>
<td>1.02</td>
<td>1.16</td>
</tr>
</tbody>
</table>

*a*Indicates a significant difference. The data in this table correspond to Fig. 3D and E.
GTT was performed at 12 weeks to analyze the ability of AKT1Myr mice to clear glucose from the blood. While both models exhibited glucose intolerance, serum insulin and glucagon levels measured during the GTT revealed that the molecular mechanisms driving the deregulations were different. As previously reported (Cho et al. 2001, Garofalo et al. 2003), AKT2KO mice had hyperinsulinemia, which was evident before the glucose injection and 45 min after the injection. Ultimately, the AKT2KO mice model a classic, insulin-based deregulation, in which early insulin resistance leads to compensatory hyperinsulinemia and eventually late insulin deficiency (Matthaei et al. 2000). When compared to WT mice, AKT1Myr mice did not have elevated fasted insulin levels. However, insulin levels were significantly higher 45 min after the injection. This increase in insulin secretion may be \(\beta\)-cell compensation and may have occurred in response to the hyperglycemia also observed at this time point. This suggests that the model a classic, insulin-based deregulation, in which early insulin resistance leads to compensatory hyperinsulinemia and eventually late insulin deficiency (Matthaei et al. 2000). When compared to WT mice, AKT1Myr mice did not have elevated fasted insulin levels. However, insulin levels were significantly higher 45 min after the injection. This increase in insulin secretion may be \(\beta\)-cell compensation and may have occurred in response to the hyperglycemia also observed at this time point. This suggests that the

Figure 4

Insulin resistance in the liver of AKT1Myr mice. One week following the GTT, (B) an insulin tolerance test was performed \((n = 5)\). (A) Area under the curve \((P<0.04)\). To analyze insulin signaling, mice were insulin-stimulated. Two minutes after injection, the mice were euthanized and the pancreas, (C) liver, (D) adipose tissue, and (E) skeletal muscle were collected and protein extracted and analyzed with insulin receptor (IR) total and IR (pY1158) ELISAs. All phospho-IR measurements were normalized to their total IR measurements.

(F) Homeostatic model assessment for insulin resistance (HOMA-IR) was calculated using the following measurements from the GTT: \((\text{fasted glucose \times fasted insulin)/405})\. Data represented as mean \(\pm\) S.E.M. Unpaired Student's \(t\)-tests were used to analyze differences in the insulin tolerance tests time points. One-way ANOVA followed by Student's \(t\)-tests within groups were used to analyze the data for A, C, D, E and F. Letters were used to illustrate significance as multiple groups are being compared (see the ‘Materials and methods’ section for explanation).

Figure 5

Decreased pancreas and islet size, with aging, in AKT1Myr mice. Pancreas size was measured upon euthanization and dissection using a digital scale \((n = 5)\) in (A) 12-week- and (B) 16-month- \((P = 0.0049)\) old mice. Islet size \((n = 50\) islets) was also measured at (C) 12 weeks and (D) 16 months \((P = 0.008)\). Islet diameter was determined analyzing H&E stained sections through Axio Imaging Software. Unpaired Student's \(t\)-tests were used to analyze A, B, C and D. Data represented as mean \(\pm\) S.E.M. Letters were used to illustrate significance as multiple groups are being compared (see the ‘Materials and methods’ section for explanation).
elevated blood glucose levels were not due to a lack of insulin production or secretion, but reduced insulin sensitivity (Weir & Bonner-Weir 2004).

While insulin deregulations are well studied, glucagon deregulations have been acknowledged but relatively ignored. Glucagon, which is secreted by pancreatic α-cells when blood glucose levels are low, is known as the antagonist to insulin. When glucagon binds to its receptor it activates cellular cAMP and protein kinase A (PKA) signaling to induce hepatic gluconeogenesis and glycogenolysis restoring glucose homeostasis during fasting (Moon & Won 2015). Increased PKA activity impairs glucose stimulated insulin secretion (GSIS), which is needed to prevent the immediate secretion and glucose-disposing action of insulin (Song et al. 2014). Serum glucagon levels in AKT2KO mice were similar to WT mice. However, AKT1Myr mice had significantly elevated fasted glucagon levels, which returned to WT levels by the 45-min time point, most likely due to the surge in insulin secretion.

Fasted hyperglucagonemia, as seen in AKT1Myr mice, has been observed in diabetic patients (Unger et al. 1970, Baron et al. 1987, Reaven et al. 1987) and linked to the manifestation of fasted hyperglycemia and glucose intolerance. The mechanisms behind hyperglucagonemia are still relatively unclear, but it has been shown to result from the inadequate response of α-cells to elevated blood glucose levels (Rizza 2010). This α-cell dysfunction leads to hepatic insulin resistance (Basu et al. 2004a), causing non-fasted hyperglycemia by preventing the suppression of endogenous glucose production during a meal, and fasted hyperglycemia via chronically elevated endogenous glucose production (Firth et al. 1986, Basu et al. 2000). The hyperglucagonemia-induced hepatic insulin resistance also significantly decreases hepatic glucose uptake and disposal due to impaired glucokinase activity (Wajngot et al. 1991, Caro et al. 1995). This impaired hepatic glucose metabolism has been identified in mild and severe diabetes patients making it an early contributing event in the pathogenesis of diabetes and not simply an effect (Basu et al. 2004b, Bock et al. 2007).

One week following the GTT, an insulin tolerance test was performed to analyze the sensitivity of insulin-responsive tissues in AKT1Myr mice. AKT1Myr mice and WT mice were not significantly different when comparing the area under the curve, suggesting an absence of insulin resistance. However, at the 15-min time point the AKT1Myr mice had significantly higher blood glucose levels than the WT mice, suggesting there may be altered insulin signaling causing this delay in insulin response. Further analysis of liver tissue revealed significantly decreased IR phosphorylation in AKT1Myr mice, compared to WT mice, despite no significant difference in IR levels. This decrease in IR activation explains the delay in insulin response seen early in the ITT and the inability of AKT1Myr mice to aptly clear glucose from the blood. Further calculation of the HOMA-IR confirmed insulin resistance in AKT1Myr mice, as compared to WT mice. However, at 12 weeks, this resistance is not as severe as the resistance seen in AKT2KO mice.

Additional longevity studies must be performed to determine whether the insulin resistance worsens with age, but analysis of pancreas and islet size suggests a gradual loss of β-cell mass. This loss of β-cell mass, evident by a decrease in total pancreas size and islet diameter, is typically indicative of long-term insulin resistance and β-cell failure due to chronic hyperinsulinemia and hyperglycemia (Prentki & Nolan 2006). There also appears to be an age-induced increase in islet diameter of WT mice. This is most likely due to naturally occurring β-cell compensation or the presence of islet adenomas, which also develop naturally in about 33% of our aged WT mice.

In this study, we characterized the pre-tumor, pre-diabetic phenotype of AKT1Myr mice, which exhibit non-fasted hyperglycemia as early as weaning and fasted hyperglycemia by 5 months of age, regardless of sex. Based upon previous findings, this hyperglycemia is likely due to α-cell dysfunction, specifically hyperglucagonemia. Although the mechanisms behind hyperglucagonemia are still relatively unclear, we are proposing that AKT1Myr mice, with fasted hyperglucagonemia, have impaired GSIS, resulting in glucose intolerance despite increased compensatory insulin secretion. Hepatic insulin resistance, an additional factor, may exacerbate the problem, preventing normoglycemia via increased hepatic glucose production and decreased hepatic glucose storage. As the fasted and non-fasted hyperglycemia are reversible when the Akt1Myr transgene is suppressed, we have attributed this diabetic phenotype to the constitutive activation of AKT1 in the pancreas of this mouse model. Collectively, this pre-diabetic model highlights a novel glucagon-mediated mechanism by which AKT1 hyperactivation affects glucose homeostasis and provides a means to better delineate molecular mechanisms contributing to diabetes mellitus and perhaps future association between diabetes and a subset of pancreatic cancers.

Declaration of interest
The authors declare that there is no conflict of interest that could be perceived as prejudicing the impartiality of the research reported.
Funding
This work was supported by the National Cancer Institute (NCI) grant R21 (CA129302 to D A A); the University of Central Florida (UCF) Gerontology Applied Research Fellowship from the Learning Institute for Elders at UCF (MEDI00041); the Florida Ladies Auxiliary to the Veterans of Foreign Wars (MDI000177); the UCF Burnett School of Biomedical Sciences (BSBS) Startup Funds (20070716), and the National Institute on Aging (AG032290 to M M M). T M A was supported in part by a McKnight Graduate Fellowship provided by the Florida Education Fund.

Author contribution statement
T M A designed the study, performed all of the experiments, and prepared this manuscript. V P assisted in all of the metabolism studies (GTT, ITT, and insulin stimulation). L P S assisted with breeding, weaning, genotyping, and glucose testing. M M M served as an expert consultant on all metabolism experiments. D A A, the corresponding author, provided financial support and supervised the project. All authors were involved in the editing of this manuscript.

Acknowledgements
R21 CA129302 supported the initial studies of glucose deregulation. Completion of the work was supported by donations from the Learning Institute for Elders at UCF and the Florida Ladies Auxiliary to the Veterans of Foreign Wars. BSBS shared core equipment resources for histology, and UCF animal care facilities were used for this study.

References
Baron AD, Schaeffer L, Shragg P & Kollerman OG 1987 Role of hyperglucagonemia in maintenance of increased rates of hepatic glucose output in type II diabetics. Diabetes 36 274–283. (doi:10.2337/ diab.36.3.274)
Holland AM, Hale MA, Kagami H, Hammer RE & MacDonald RJ 2002
Experimental control of pancreatic development and maintenance.

Kim JH, Stewart TP, Soltani-Bejnood M, Wang L, Fortuna JM, Mostafa OA,
Phenotypic characterization of polygenic type 2 diabetes in TALLYHO/JngJ mice.
*Journal of Endocrinology* 191 437–446. (doi:10.1677/joe.1.06647)

Kushner JA, Simpson L, Wartschow LM, Guo S, Rankin MM, Parsons R &
White MF 2005 Phosphatase and tensin homolog regulation of islet
growth and glucose homeostasis.
*Journal of Biological Chemistry* 280 39388–39393. (doi:10.1074/jbc.M504155200)

Matthaei S, Stumvoll M, Kellerer M & Häring HU 2000 Pathophysiology
and pharmacological treatment of insulin resistance.
*Endocrine Reviews* 21 585–618. (doi:10.1210/edrv.21.6.0413)

Missiaglia E, Dalai I, Barbi S, Beghelli S, Falconi M, della Peruta M, Piemonti L,
Capurso G, Di Florio A, delle Fave G et al. 2010 Pancreatic endocrine
tumors: expression profiling evidences a role for AKT–mTOR pathway.

Moon JS & Won KC 2015 Pancreatic α-cell dysfunction in type 2 diabetes:
old kids on the block.

*Journal of Clinical Investigation* 116 1802–1812. (doi:10.1172/JCI29103)

Reaven GM, Chen YD, Golay A, Swiłołcki AL & Jaspan JB 1987
Documentation of hyperglucagonemia throughout the day in non-obese
and obese patients with noninsulin-dependent diabetes mellitus.
*Journal of Clinical Endocrinology and Metabolism* 64 106–110.
(doi:10.1210/jcem-64-1-106)

Rizza RA 2010 Pathogenesis of fasting and postprandial hyperglycemia in
type 2 diabetes: implications for therapy.
*Diabetes* 59 2697–2707. (doi:10.2337/db10-1032)

Schlieman MG, Fahy BN, Ramsamojoor R, Beckett L & Bold RJ 2003
Incidence, mechanism and prognostic value of activated AKT in
pancreas cancer.
*British Journal of Cancer* 89 2110–2115. (doi:10.1038/sj.bjc.6601396)

Song WJ, Mondal P, Wolfe A, Alonso LC, Stamateris R, Ong BW, Lim OC,
Yang KS, Radovick S, Novaira HJ et al. 2014 Glucagon regulates hepatic
kisspeptin to impair insulin secretion.
*Cell Metabolism* 19 667–681. (doi:10.1016/j.cmet.2014.03.005)

Received in final form 2 October 2015
Accepted 20 October 2015
Accepted Preprint published online 20 October 2015